Bleomycin delivery by osmotic minipump: Similarity to human scleroderma interstitial lung disease

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 306, Issue 8, 2014, Pages

  Lee, Rebecca ^a   Reese, Charles ^a   Bonner, Michael ^a   Tourkina, Elena ^a   Hajdu, Zoltan ^a   Riemer, Ellen C ^a   Silver, Richard M ^a   Visconti, Richard P ^a   Hoffman, Stanley ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Fibrosis; Inflammation; Type II pneumocytes

Indexed keywords

BLEOMYCIN; CAVEOLIN 1; HEAT SHOCK PROTEIN 47;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; LUNG INJURY; MORTALITY; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SCLERODERMA; SCLERODERMA INTERSTITIAL LUNG DISEASE; SKIN FIBROSIS; WEIGHT REDUCTION; WESTERN BLOTTING;

FIBROSIS; INFLAMMATION; TYPE II PNEUMOCYTES;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CAVEOLIN 1; DRUG DELIVERY SYSTEMS; EXTRACELLULAR MATRIX PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; INFUSION PUMPS; LUNG DISEASES, INTERSTITIAL; MALE; MICE; MICE, INBRED C57BL; OSMOSIS; PULMONARY ALVEOLI; SCLERODERMA, SYSTEMIC; WEIGHT LOSS;

EID: 84900560078     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00210.2013     Document Type: Article

References (30)

1. Aono Y, Ledford JG, Mukherjee S, Ogawa H, Nishioka Y, Sone S, Beers MF, Noble PW, Wright JR. Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. Am J Respir Crit Care Med 185: 525-536, 2012.
2. Borchers AT, Chang C, Keen CL, Gershwin ME. Idiopathic pulmonary fibrosis-an epidemiological and pathological review. Clin Rev Allergy Immunol 40: 117-134, 2011.
3. Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 33: 9-13, 2005.
4. Decologne N, Wettstein G, Kolb M, Margetts P, Garrido C, Camus P, Bonniaud P. Bleomycin induces pleural and subpleural fibrosis in the presence of carbon particles. Eur Respir J 35: 176-185, 2010.
5. Degryse AL, Lawson WE. Progress toward improving animal models for idiopathic pulmonary fibrosis. Am J Med Sci 341: 444-449, 2011.
6. Degryse AL, Tanjore H, Xu XC, Polosukhin VV, Jones BR, McMahon FB, Gleaves LA, Blackwell TS, Lawson WE. Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 299: L442-L452, 2010.
7. Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 380: 689-698, 2012.
8. Gulati M. Diagnostic assessment of patients with interstitial lung disease. Primary Care Respir J 20: 120-127, 2011.
9. Harrison JH Jr, Lazo JS. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J Pharmacol Exp Ther 243: 1185-1194, 1987.
10. Hubner RH, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, Freitag-Wolf S, Bewig B. Standardized quantification of pulmonary fibrosis in histological samples. BioTechniques 44: 507-517, 2008.
11. Ichikawa T, Matsuda A, Miyamoto K, Tsubosaki M, Umezawa H. Biological studies on bleomycin A. J Antibiot (Tokyo) 20: 149-155, 1967.
12. Ishida Y, Nagata K. Hsp47 as a collagen-specific molecular chaperone. Methods Enzymol 499: 167-182, 2011.
13. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 378: 1949-1961, 2011.
14. Marangoni R, Wei J, Hinchcliff M, Fang F, Tourtellotte W, Varga J. Aberrant adipogenesis in the pathogenesis of scleroderma. Arthritis Rheum 64: S341-S342, 2012.
15. Markart P, Wygrecka M, Guenther A. Update in diffuse parenchymal lung disease 2010. Am J Respir Crit Care Med 183: 1316-1321, 2011.
16. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? In J Biochem Cell Biol 40: 362-382, 2008.
17. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294: L152-L160, 2008.
18. Mouratis MA, Aidinis V. Modeling pulmonary fibrosis with bleomycin. Curr Opin Pulm Med 17: 355-361, 2011.
19. Muggia FM, Louie AC, Sikic BI. Pulmonary toxicity of antitumor agents. Cancer Treat Rev 10: 221-243, 1983.
20. Nagata K. HSP47 as a collagen-specific molecular chaperone: function and expression in normal mouse development. Semin Cell Dev Biol 14: 275-282, 2003.
21. Nagata K. Hsp47: a collagen-specific molecular chaperone. Trends Biochem Sci 21: 22-26, 1996.
22. Scotton CJ, Chambers RC. Bleomycin revisited: towards a more representative model of IPF? Am J Physiol Lung Cell Mol Physiol 299: L439-L441, 2010.
23. Taguchi T, Razzaque MS. The collagen-specific molecular chaperone HSP47: is there a role in fibrosis? Trends Mol Med 13: 45-53, 2007.
24. Tan A, Denton CP, Mikhailidis DP, Seifalian AM. Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a review. Clin Exp Rheumatol 29: S66-S74, 2011.
25. Tourkina E, Richard M, Gooz P, Bonner M, Pannu J, Harley R, Bernatchez PN, Sessa WC, Silver RM, Hoffman S. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 294: L843-L861, 2008.
26. Tourkina E, Richard M, Oates J, Hofbauer A, Bonner M, Gooz P, Visconti R, Zhang J, Znoyko S, Hatfield CM, Silver RM, Hoffman S. Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis 69: 1220-1226, 2010.
27. Umezawa H. Chemistry and mechanism of action of bleomycin. Fed Proc 33: 2296-2302, 1974.
28. Umezawa H, Ishizuka M, Maeda K, Takeuchi T. Studies on bleomycin. Cancer 20: 891-895, 1967.
29. Wang ZL. Advances in understanding of idiopathic pulmonary fibrosis. Chin Med J (Engl) 122: 844-857, 2009.
30. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2: 103-121, 2009.